Top of this page
Skip navigation, go straight to the content

ucb-usa.com Newsroom UCB U.S. News

Categories

  • 4 Phases of Clinical Research Studies

    Posted by Katelyn Snider, U.S. Communications and Public AffairsUCB_ClinicalResearch_Static_Body
    In case you missed it, last week we covered the basics of clinical research but there is a lot more to how a drug eventually makes it to patients. In fact, only 12 percent of medicines that enter clinical research will ever make it to patients.1

    Read more

  • Clinical Research 101

    Posted by Katelyn Snider, U.S. Communications and Public Affairs
    UCB_TickingNumbers_Resize_Body.gif
    Whether it is discovering a therapy that could work for an individual patient faster or finding new ways to treat the root cause of a disease, at UCB, we are committed to continuing to unlock the science to improve the lives of patients.

    Read more

  • ICYMI: UCB in the News

    Posted by Katelyn Snider, U.S. Communications and Public AffairsBlog_Photo_1280x960

    At UCB, we strive to discover and deliver new solutions patients value. Whether it’s through leveraging big data, thinking outside the box to overcome barriers, or collaborating with others in the healthcare industry—initiatives across UCB are at the forefront of research, and recently, our experts have been in the news talking about what we’re working on.

    Read more

  • Announcing the 2018 UCB Family Epilepsy Scholarship Winners

    Posted by Allyson Funk, Head of U.S. Communications and Public Relationsnew_Epilepsy_Family_Scholarship_Sized_1280x960

    UCB is pleased to announce 32 recipients were awarded the 2018 UCB Family Epilepsy Scholarship. This year’s winners are beginning their academic year at 31 schools across the country where awards will support their undergraduate or graduate education. Hailing from 17 states, this diverse group of passionate advocates includes people living with epilepsy or caregiving for someone living with epilepsy, including parents and siblings.

    Read more

  • Where is She Now? Reflections from UCB’s First Scholarship Winner

    Posted by

    Maria_Genco_31280x960



    As one of the first winners of the UCB Family Epilepsy Scholarship, Maria reflects on the goals, choices, and experiences that have shaped her ever-evolving career in science.

    Read more

  • The Day Psoriasis Stopped Stopping Me

    Posted by

    Alisha_Bridges_1280x960

    As part of Psoriasis Action Month, Alisha Bridges, an award-winning writer and community advocate, recently shared her story about living with psoriasis.

    Read more

  • UCB Runners Lace Up to Support Patients

    Posted by Katelyn Snider, U.S. Communications and Public Affairs9q0ipi0055.gif

    UCB supports local events across the country that benefit patients. Recently, our employees participated in two different runs in support of the epilepsy and Crohn’s disease communities.

    Read more

  • Press Release: FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters

    UCB_LOGO_1280x960

    FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters

    Read more

  • New Resource for Those Living with Spondyloarthritis

    Posted by Jeffrey Stark, M.D., Head of Medical Affairs, Rheumatology MHT_Spondylitis_Webpage_1280v960_for_Blog

    An estimated 3.3 million individuals in the U.S. are living with spondyloarthritis1,2 (SpA), an inflammatory disease affecting the spine, and in some people, the joints of the arms and legs, skin, intestines, and eyes. An underdiagnosed condition, most people with SpA first experience symptoms in their 20s or 30s but typically wait as many as 10 years between symptom onset and SpA diagnosis. *

    Read more

  • Disease Spotlight: Psoriasis

    Posted by Katelyn Snider, U.S. Communications and Public AffairsPsO_Patient_1280x960

    August is Psoriasis Awareness Month so we’re shining a spotlight on the disease and how UCB is working to deliver solutions that patients value.

    Read more